Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 01, 2025, titled "Sentynl Therapeutics updates on its NDA for CUTX-101".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has shared a press release from its subsidiary Sentynl Therapeutics regarding an update on the New Drug Application (NDA) for CUTX-101. CUTX-101 is an investigational therapy developed for Menkes disease, a rare genetic disorder affecting copper metabolism in infants. The filing refers to a press release dated October 01, 2025. No specific outcome, approval status, or financial figures were disclosed in this filing, as it is simply an intimation that the press release has been forwarded to the exchange.
This is a routine regulatory disclosure with no immediate material impact on the stock. Investors should look for the actual press release from Sentynl Therapeutics for details on the NDA status, as progress or setbacks on rare-disease drug approvals can influence long-term valuation through Zydus's specialty therapeutics portfolio.